Guangzhou's Biopharma Innovation: Accelerating Local Drug Development and Global Integration

Currently serves as Executive Director and General Manager of Guangzhou Shangjun Investment Consulting Co., Ltd., and is also a Standing Committee Member of the Medical Innovation and Translation Expert Committee of the Guangdong Provincial Medical Association, as well as the Executive Secretary-General of the China-Europe Science and Technology Investment Promotion Association.

Focused on investment and ecosystem development in the healthcare industry, we have established an international financial innovation platform for life sciences. This one-stop platform integrates consulting, investment, in-depth project services, and resource integration to facilitate the commercialization of innovative scientific and technological achievements originating from universities, research institutes, and medical institutions. By linking and collaborating closely with innovative enterprises, investment firms, medical institutions, service providers, think tanks, and government organizations, we are committed to building a globally leading life sciences ecosystem.

With nearly 20 years of experience in the financial industry, he previously served as Assistant General Manager of the Financial Management Department at Guangzhou Financial Holdings Group and as Deputy General Manager of Guangzhou Financial Holdings Fund Management Co., Ltd. Throughout his career, he has cultivated a deep presence in the Guangzhou market, possessing thorough knowledge of the development trajectory of Guangzhou’s financial sector and expertise across various financial products, along with extensive experience in financial management and project investment operations. During his tenure in the Finance Department of Guangzhou Financial Holdings Group, he participated in Bank of Guangzhou’s asset restructuring and strategic investor introduction projects. While at Guangzhou Financial Holdings Fund and Guangzhou Health Industry Investment, he helped initiate and manage the establishment of multiple primary-market equity investment funds and funds of funds (FOFs), with assets under management exceeding RMB 5 billion. He has invested in numerous early- to mid-stage projects, including GAC Aion, Aulton New Energy, ChipON International, Baiji Biology, Ruifeng Biology, and Saiton Medical.

Ph.D. in Biochemistry and Molecular Biology from the Fourth Military Medical University; Founder of Feichuang Biomedical Technology (Guangzhou) Co., Ltd.; Jointly appointed researcher at Guangzhou Laboratory and Guangzhou Medical University; Chairperson of the Committee on Integrated Diagnosis and Treatment of Fibrosis, Guangdong Provincial Society for Respiratory Health. He has long been dedicated to the research, development, and translation of diagnostic and therapeutic strategies for organ fibrosis-related diseases, committed to establishing a full-chain pathway from laboratory to clinic and from technology to product.

Pioneered the identification of limitations in the gold standard for preclinical evaluation of pulmonary fibrosis, and developed targeted novel evaluation models and efficacy assessment systems. The team has secured over RMB 3 million in funding for corporate innovative anti-fibrotic drug efficacy evaluation projects, providing critical technical support for the development of new pulmonary fibrosis drugs in China. Developed novel detection methods for blood biomarkers of pulmonary fibrosis, obtaining dual invention patents in China and Japan, and successfully integrated into third-party medical testing systems to achieve clinical implementation.

Currently serving as the General Secretary of the Party Branch at Najin Technology Industrial Park and General Manager of Guangzhou Najin Technology Co., Ltd., he previously worked in relevant government departments of Guangdong Province. He has extensive expertise in industrial park operations and the cultivation of hard-tech industries, such as biomedicine. Currently, he oversees the comprehensive management of nearly 1 million square meters of “specialized incubators + premium science parks” under Najin High-Tech, serving over 1,000 enterprises with a strategic focus on high-tech sectors including biomedicine and intelligent manufacturing. Adhering to long-term value principles, he has built a “full-chain, one-stop, full-lifecycle” enterprise empowerment system, creating an industrial ecosystem where “the industrial park is the industrial chain, and moving between floors means engaging with upstream and downstream partners.” He innovatively launched the “Najin 30 Measures” service package to address key pain points in enterprise development. Under his leadership, the park has obtained numerous qualifications, including National-Level Science and Technology Enterprise Incubator, Guangdong Provincial Science and Technology Enterprise Accelerator, and China’s Demonstration Base for Entrepreneurship and Innovation of Small and Micro Enterprises. It has also established professional platforms such as the Guangzhou SME Public Service Demonstration Platform, Sci-Tech Finance Workstation, Trade Promotion Workstation, Biomedical Venture Capital Workstation, and Innovation Service Workstation. By integrating resources from government, capital, medical institutions, and enterprises, he has bridged the “last mile” of industrial services, promoting the integration of industry and medicine as well as supply chain collaboration. Deeply engaged in building the industrial ecosystem of the Guangdong-Hong Kong-Macao Greater Bay Area, he contributes to the high-quality development of hard-tech industry clusters and the innovative upgrading of the biomedical industry.